Evolent Health (NYSE: EVH) reported Q1 EPS of $0.34, $0.13 better than the analyst estimate of $0.21. Revenue for the quarter came in at $639.65 million versus the consensus estimate of $600.82 million.

GUIDANCE:

Evolent Health sees Q2 2024 revenue of $625-645 million, versus the consensus of $606.6 million.

Evolent Health sees FY2024 revenue of $2.53-2.6 billion, versus the consensus of $2.467 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.